Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H40N4 |
| Molecular Weight | 408.6226 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(CCCCCCC1)N2CCC(CC2)N3C(=NC4=CC=CC=C34)[C@@H]5CCCNC5
InChI
InChIKey=CYYNMPPFEJPBJD-OAQYLSRUSA-N
InChI=1S/C26H40N4/c1-26(15-7-3-2-4-8-16-26)29-18-13-22(14-19-29)30-24-12-6-5-11-23(24)28-25(30)21-10-9-17-27-20-21/h5-6,11-12,21-22,27H,2-4,7-10,13-20H2,1H3/t21-/m1/s1
| Molecular Formula | C26H40N4 |
| Molecular Weight | 408.6226 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
MCOPPB trihydrochloride (MCOPPB) is a nonpeptide agonist of the NOP receptor, an anxiolytic agent. MCOPPB has a high affinity for the human NOP receptor (pKi = 10.07 +/- 0.01) and selectivity for the NOP receptor over other members of the opioid receptor family: 12-, 270- and >1000-fold more selective for the NOP receptor than for the micro-, kappa-, and delta-receptor, respectively. In an ex vivo binding study, MCOPPB (10 mg/kg, p.o.) inhibited signaling through the NOP receptor in the mouse brain, suggesting that it penetrated into the brain after it was orally administered. MCOPPB - a compound with few adverse effects on the central nervous system - is a potential therapeutic agent for the treatment of anxiety.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18319566 | https://www.ncbi.nlm.nih.gov/pubmed/19125610
Curator's Comment: # Pfizer Inc., Japan
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacological characterization of the newly synthesized nociceptin/orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole as an anxiolytic agent. | 2008 Mar |
|
| Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent antianxiety drug. | 2009 Feb 12 |
|
| Quantitative Signaling and Structure-Activity Analyses Demonstrate Functional Selectivity at the Nociceptin/Orphanin FQ Opioid Receptor. | 2015 Sep |
Patents
Sample Use Guides
Mice: In the mouse Vogel conflict test, MCOPPB trihydrochloride (10 mg/kg, p.o.) and diazepam (3 mg/kg, p.o.) elicited anxiolytic-like effects, although MCOPPB trihydrochloride produced a bell-shaped response curve. In addition, MCOPPB (10 mg/kg, p.o.) was still effective as an anxiolytic agent even after repeated administration for 5 days.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:33:21 GMT 2023
by
admin
on
Sat Dec 16 15:33:21 GMT 2023
|
| Record UNII |
8NMK0UG3HV
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
8NMK0UG3HV
Created by
admin on Sat Dec 16 15:33:22 GMT 2023 , Edited by admin on Sat Dec 16 15:33:22 GMT 2023
|
PRIMARY | |||
|
1028969-49-4
Created by
admin on Sat Dec 16 15:33:22 GMT 2023 , Edited by admin on Sat Dec 16 15:33:22 GMT 2023
|
PRIMARY | |||
|
24800108
Created by
admin on Sat Dec 16 15:33:22 GMT 2023 , Edited by admin on Sat Dec 16 15:33:22 GMT 2023
|
PRIMARY | |||
|
DTXSID401018254
Created by
admin on Sat Dec 16 15:33:22 GMT 2023 , Edited by admin on Sat Dec 16 15:33:22 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
